Literature DB >> 6591853

In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.

J T Rudrik, S J Cavalieri, E M Britt.   

Abstract

Enoxacin (CI-919) was evaluated for activity against 120 multiply resistant clinical isolates of the family Enterobacteriaceae and Pseudomonas aeruginosa. The MIC of enoxacin for 95% of the strains tested was less than or equal to 2 micrograms/ml. Approximately 90% of the isolates were susceptible to enoxacin, norfloxacin, ceftazidime, moxalactam, cefotaxime, cefoperazone, and amikacin. Marked resistance to the other seven antimicrobial agents tested was observed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6591853      PMCID: PMC179926          DOI: 10.1128/AAC.26.1.97

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.

Authors:  S Nakamura; A Minami; H Katae; S Inoue; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

2.  In vitro and in vivo antibacterial activity of AT-2266.

Authors:  K Kouno; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

3.  Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.

Authors:  S Nakamura; N Kurobe; S Kashimoto; T Ohue; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

4.  Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715).

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

5.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

6.  In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.

Authors:  S A Chartrand; R K Scribner; A H Weber; D F Welch; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

7.  Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.

Authors:  S Nakamura; K Nakata; H Katae; A Minami; S Kashimoto; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

  7 in total
  7 in total

Review 1.  The future of new oral antibiotics including the quinolones.

Authors:  M G Bergeron
Journal:  CMAJ       Date:  1988-01-01       Impact factor: 8.262

2.  Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project.

Authors:  T A Kurzynski; D M Boehm; J A Rott-Petri; R F Schell; P E Allison
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

Review 3.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 4.  Transferable Mechanisms of Quinolone Resistance from 1998 Onward.

Authors:  Joaquim Ruiz
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

5.  Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Authors:  G H Talbot; P A Cassileth; L Paradiso; R Correa-Coronas; L Bond
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

6.  The effect of age on the pharmacokinetics of enoxacin.

Authors:  B R Dobbs; L R Gazeley; A J Campbell; I R Edwards
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 7.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.